High-throughput technologies have dramatically improved our understanding of acute leukemia pathogenesis. Omics-based personalized approaches have the potential to offer individualized, highly specific therapies. Currently most of them exploit the phenomenon of ‘oncogene addiction’: tumor cells depend on an oncogene/oncogenic pathway for survival. However, for tumors with no targetable gain-of-function oncogenes the therapy is still based on DNA-damaging agents. In these tumors it is possible to identify patient-specific secondary targets whose disruption in conjunction with genomic alteration results in synthetic lethality (SL). There are two possible SL approaches: Gene to Drug (G-D), where the synergism is reached by associating a primary genetic alteration with a secondary drug; Drug to Drug (D-D), where the synergism is reached by combining the effect of two different drugs. Our aim is to develop a machine learning-based model to predict personalized treatment for relapsed/refractory acute leukemias. We will exploit the above-mentioned SL approaches by multilayer analysis of omics data, including RNA-Seq, Copy Number Alterations (CNAs) by SNP array and DNA targeted Next Generation Sequencing (WP2). Differential expression analysis of RNA-Seq data will provide primary molecular markers that will be propagated in protein-protein interaction networks, to identify secondary nonaltered potential markers (in parallel for G-D SL and D-D SL). The candidates will be reduced by selecting DDR-related genes for which a drug inhibitor is known (WP3). The selected drugs will be screened ex-vivo to identify the most effective for each patient (WP4). The integrated omics data and ex-vivo test results will be used as training dataset for the predictive model (WP3). Finally, a multi-centric investigator-initiated clinical trial will test the performance of the predictive model as well as the practical feasibility of the whole procedure (WP1-5).
leucemia aguda
letalidad sintética
medicina personalizada
big data
macrodatos
ómica
desenlace del paciente
Acción Estratégica en Salud (AES)
01/01/2019 - 31/12/2021
HERNANDEZ RIVAS, JESUS MARIA
FUNDACION INSTITUTO DE ESTUDIOS DE CIENCIAS DE LA SALUD DE CASTILLA Y LEON
INSTITUTO DE INVESTIGACION BIOMEDICA DE SALAMANCA (IBSAL)
Castilla y León
Salamanca
200,000 €